US Nuclear Corp. Announces Third Quarter 2023 Results
US Nuclear Corp. Announces Third Quarter 2023 Results
LOS ANGELES, CA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –US Nuclear Corp. (OTC-QB: UCLE), a leading manufacturer of advanced radiation, chemical, and biological detection and UAV instrumentation, recently announced the financial results for the third quarter ended September 30, 2023.
加利福尼亞州洛杉磯，2023年11月29日（GLOBE NEWSWIRE）——通過NewMediaWire——先進輻射、化學和生物探測以及無人機儀器的領先製造商美國核公司（場外交易代碼：UCLE）最近公佈了截至2023年9月30日的第三季度財務業績。
For the three months ended September 30, 2023:
在截至2023年9月30日的三個月中：
- Sales were $593,502 compared to $617,434 for the same period in 2022
- Cost of goods decreased by a factor of 3 compared to the same period in 2022, from 66% to only 22%
- Gross margins increased by 44.15% due to a mix of enhanced manufacturing efficiency and higher margin products sold during the period. The Company expects this trend to continue due to increased sales of US Nuclear's premium highly valued, specialized products.
- Selling, general and administrative expenses were $539,339 compared to $695,381 for the same period in 2022, a decrease of $156,042 or 28.93%
- Loss from operations decreased by a factor of 7 and was $73,562 compared to $483,419 for the same period in 2022
- Net loss was $760,062 compared to $655,822 for the same period in 2022
- 銷售額爲593,502美元，而2022年同期爲617,434美元
- 與2022年同期相比，商品成本下降了3倍，從66％降至僅22％
- 毛利率增長了44.15％，這要歸因於在此期間銷售的製造效率提高和利潤率更高的產品。該公司預計，由於US Nuclear的高價值專業產品的銷售增加，這種趨勢將持續下去。
- 銷售、一般和管理費用爲539,339美元，而2022年同期爲695,381美元，下降了156,042美元，下降了28.93％
- 運營虧損下降了7倍，爲73,562美元，而2022年同期爲483,419美元
- 淨虧損爲760,062美元，而2022年同期爲655,822美元
Robert Goldstein, CEO of US Nuclear Corp., commented:
"We are pleased to report another quarter of strong performance. The results underscore our team's commitment to driving sales revenue while reducing expenses on our path to profitability, and our ability to capitalize on the increasing demand for our innovative radiation detection solutions. We drastically increased our gross margins by 44.15% by streamlining our production and manufacturing efficiency and by selling our specialized products to buyers willing to pay for our premium product quality and functionality. We expect this trend to continue and a ramp-up in sales revenue will translate into profitable operating income. The launch of several unique new chemical detectors for detecting drugs (fentanyl), explosives, chemical warfare agents and even PFAS "forever chemicals" will be a sales catalyst moving forward, in addition to increased demand for our tritium monitoring instrumentation which is direly needed as fusion power research and operation ramps up."
美國核公司首席執行官羅伯特·戈德斯坦評論說：
“我們很高興地報告了又一個季度的強勁表現。這些結果凸顯了我們的團隊致力於在提高銷售收入的同時減少盈利之路上的支出，也凸顯了我們有能力利用對創新輻射探測解決方案不斷增長的需求。通過簡化生產和製造效率以及向願意爲我們的優質產品質量和功能付費的買家出售我們的專業產品，我們將毛利率大幅提高了44.15％。我們預計這種趨勢將持續下去，銷售收入的增加將轉化爲有利可圖的營業收入。幾款用於檢測毒品（芬太尼）、爆炸物、化學戰劑甚至全氟辛烷磺酸 “永恒化學品” 的獨特的新型化學探測器的推出將成爲未來的銷售催化劑，此外隨着聚變能研究和運營的加快，對我們的氘監測儀器的需求也將增加。”
| US NUCLEAR CORP. AND SUBSIDIARIES | ||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||
| (unaudited) | ||||||||||
| Three Months Ended | ||||||||||
| September 30, | ||||||||||
| 2023 | 2022 | |||||||||
| Sales | $593,502 | $617,434 | ||||||||
| Cost of sales | 127,727 | 22% | 405,471 | 66% | ||||||
| Gross profit | 465,775 | 78% | 211,963 | 34% | ||||||
| Operating expenses | ||||||||||
| Selling, general and administrative expenses | 539,337 | 695,381 | ||||||||
| Total operating expenses | 539,337 | 695,381 | ||||||||
| Loss from operations | 73,562 | 15% | 483,419 | ) | ||||||
| Other income (expense) | ||||||||||
| Interest expense | (27,795 | ) | (31,710 | ) | ||||||
| Equity loss in investment | - | - | ||||||||
| Loss on deconsolidation | - | - | ||||||||
| Amortization of debt discount | (658,705 | ) | (140,693 | ) | ||||||
| Total other income (expense) | (686,500 | ) | (172,403 | ) | ||||||
| Loss before provision for income taxes | (760,062 | ) | (655,822 | ) | ||||||
| Provision for income taxes | - | - | ||||||||
| Net loss | $(760,062 | ) | $(655,822 | ) | ||||||
| Deemed dividend for down-round provision in warrants | - | - | ||||||||
| Net loss attributed to common stockholders | $(760,062 | ) | $(655,822 | ) | ||||||
| Weighted average shares outstanding - basic and diluted | 36,237,707 | 29,504,433 | ||||||||
| Loss per shares - basic and diluted | $(0.02 | ) | $(0.02 | ) | ||||||
| The accompanying notes are an integral part of these | ||||||||||
| unaudited condensed consolidated financial statements. | ||||||||||
| US NUCLEAR CORP. AND SUBSIDIARIES | ||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||
| (unaudited) | ||||||||||
| Nine Months Ended | ||||||||||
| September 30, | ||||||||||
| 2023 | 2022 | |||||||||
| Sales | $1,588,009 | $1,539,517 | ||||||||
| Cost of sales | 651,992 | 837,523 | ||||||||
| Gross profit | 936,017 | 701,994 | ||||||||
| Operating expenses | ||||||||||
| Selling, general and administrative expenses | 1,875,583 | 2,103,637 | ||||||||
| Total operating expenses | 1,875,583 | 2,103,637 | ||||||||
| Loss from operations | (939,565 | ) | (1,401,644 | ) | ||||||
| Other income (expense) | ||||||||||
| Interest expense | (70,635 | ) | (37,650 | ) | ||||||
| Equity loss in investment | (8,059 | ) | - | |||||||
| Loss on deconsolidation | (2,539 | ) | - | |||||||
| Amortization of debt discount | (1,275,316 | ) | (232,449 | ) | ||||||
| Total other income (expense) | (1,356,549 | ) | (270,099 | ) | ||||||
| Loss before provision for income taxes | (2,296,114 | ) | (1,671,743 | ) | ||||||
| Provision for income taxes | - | - | ||||||||
| Net loss | $(2,296,114 | ) | $(1,671,743 | ) | ||||||
| Deemed dividend for down-round provision in warrants | (2,013 | ) | (9,652 | ) | ||||||
| Net loss attributed to common stockholders | $(2,298,127 | ) | $(1,681,395 | ) | ||||||
| Weighted average shares outstanding - basic and diluted | 35,049,921 | 28,923,132 | ||||||||
| Loss per shares - basic and diluted | $(0.07 | ) | $(0.06 | ) | ||||||
| 美國核公司和子公司 | ||||||||||
| 簡明合併運營報表 | ||||||||||
| （未經審計） | ||||||||||
| 三個月已結束 | ||||||||||
| 9月30日 | ||||||||||
| 2023 | 2022 | |||||||||
| 銷售 | 593,502 美元 | 617,434 美元 | ||||||||
| 銷售成本 | 127,727 | 22% | 405,471 | 66% | ||||||
| 毛利 | 465,775 | 78% | 211,963 | 34% | ||||||
| 運營費用 | ||||||||||
| 銷售、一般和管理費用 | 539,337 | 695,381 | ||||||||
| 運營費用總額 | 539,337 | 695,381 | ||||||||
| 運營損失 | 73,562 | 15% | 483,419 | ) | ||||||
| 其他收入（支出） | ||||||||||
| 利息支出 | (27,795) | ) | (31,710) | ) | ||||||
| 投資中的股權損失 | - | - | ||||||||
| 拆除合併造成的損失 | - | - | ||||||||
| 債務折扣的攤銷 | (658,705) | ) | (140,693) | ) | ||||||
| 其他收入總額（支出） | (686,500) | ) | (172,403) | ) | ||||||
| 所得稅準備金前的虧損 | (760,062) | ) | (655,822) | ) | ||||||
| 所得稅準備金 | - | - | ||||||||
| 淨虧損 | $ (760,062) | ) | $ (655,822) | ) | ||||||
| 認股權證下行準備金的視爲分紅 | - | - | ||||||||
| 歸因於普通股股東的淨虧損 | $ (760,062) | ) | $ (655,822) | ) | ||||||
| 加權平均已發行股票——基本股和攤薄後股票 | 36,237,707 | 29,504,433 | ||||||||
| 每股虧損——基本虧損和攤薄 | $ (0.02) | ) | $ (0.02) | ) | ||||||
| 隨附的註釋是這些註釋不可分割的一部分 | ||||||||||
| 未經審計的簡明合併財務報表。 | ||||||||||
| 美國核公司和子公司 | ||||||||||
| 簡明合併運營報表 | ||||||||||
| （未經審計） | ||||||||||
| 九個月已結束 | ||||||||||
| 9月30日 | ||||||||||
| 2023 | 2022 | |||||||||
| 銷售 | 1,588,009 美元 | 1,539,517 美元 | ||||||||
| 銷售成本 | 651,992 | 837,523 | ||||||||
| 毛利 | 936,017 | 701,994 | ||||||||
| 運營費用 | ||||||||||
| 銷售、一般和管理費用 | 1,875,583 | 2,103,637 | ||||||||
| 運營費用總額 | 1,875,583 | 2,103,637 | ||||||||
| 運營損失 | (939,565) | ) | (1,401,644) | ) | ||||||
| 其他收入（支出） | ||||||||||
| 利息支出 | (70,635) | ) | (37,650 | ) | ||||||
| 投資中的股權損失 | (8,059 | ) | - | |||||||
| 拆除合併造成的損失 | (2,539 | ) | - | |||||||
| 債務折扣的攤銷 | (1,275,316 | ) | (232,449) | ) | ||||||
| 其他收入總額（支出） | (1,356,549) | ) | (270,099 | ) | ||||||
| 所得稅準備金前的虧損 | (2,296,114 | ) | (1,671,743 | ) | ||||||
| 所得稅準備金 | - | - | ||||||||
| 淨虧損 | $ (2,296,114 | ) | $ (1,671,743) | ) | ||||||
| 認股權證下行準備金的視爲分紅 | (2,013) | ) | (9,652) | ) | ||||||
| 歸因於普通股股東的淨虧損 | $ (2,298,127 | ) | $ (1,681,395) | ) | ||||||
| 加權平均已發行股票——基本股和攤薄後股票 | 35,049,921 | 28,923,132 | ||||||||
| 每股虧損——基本虧損和攤薄 | $ (0.07 | ) | $ (0.06 | ) | ||||||
Safe Harbor Act
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.
《安全港法》
本新聞稿包括1995年《美國私人證券訴訟改革法》安全港條款所指的 “前瞻性陳述”。實際結果可能與預期、估計和預測不同，因此，您不應依賴這些前瞻性陳述作爲對未來事件的預測。諸如 “期望”、“估計”、“項目”、“預算”、“預測”、“預期”、“打算”、“計劃”、“可能”、“將”、“可以”、“應該”、“相信”、“預測”、“潛力”、“繼續” 等詞語以及類似的表達方式旨在識別此類前瞻性陳述。這些前瞻性陳述涉及重大風險和不確定性，可能導致實際結果與預期結果存在重大差異。
Investors may find additional information regarding US Nuclear Corp. at the SEC website at or the company's website at
投資者可以在美國證券交易委員會網站或該公司的網站上找到有關美國核公司的更多信息
CONTACT:
US Nuclear Corp. (OTC-QB: UCLE)
Robert I. Goldstein, President, CEO, and Chairman
Michael Hastings, Chief Financial Officer
(818) 883 7043
Email: info@usnuclearcorp.com
聯繫人：
美國核公司（OTC-QB：UCLE）
羅伯特·戈德斯坦，總裁、首席執行官兼董事長
邁克爾·黑斯廷斯，首席財務官
(818) 883 7043
電子郵件：info@usnuclearcorp.com